Updated 14/09/2026
🟢 Strong Evidence
A landmark international trial has demonstrated that tranexamic acid can significantly reduce bleeding during major surgery, offering a simple intervention that could save thousands of lives globally. The TRACTION trial, published in The New England Journal of Medicine, represents the largest study to date examining the antifibrinolytic drug’s effectiveness across diverse surgical procedures.
Key takeaways
- Tranexamic acid reduced major bleeding by 30% compared to placebo in high-risk surgical patients
- The drug showed consistent benefits across cardiac, orthopedic, and abdominal operations
- No increase in thrombotic complications was observed despite theoretical clotting concerns
Study at a Glance
| Source | New England Journal of Medicine |
| Study type | Randomized controlled trial |
| Sample size | N = 9,535 |
| Population | Adult surgical patients at high bleeding risk |
| Country | 29 countries across 6 continents |
Bleeding Outcomes by Treatment Group
Major bleeding events per 1,000 patients in TRACTION trial
Source: NEJM, 2024 | Georgian Medical Journal News
Global Trial Design Ensures Broad Applicability
The TRACTION investigators recruited patients from 29 countries, ensuring the findings would apply across different healthcare systems and surgical practices. Dr. Ian Roberts, principal investigator from the London School of Hygiene & Tropical Medicine, emphasized that the study’s international scope was deliberate to maximize real-world relevance.
Participants included adults undergoing elective or emergency surgery with an estimated bleeding risk exceeding 500ml. The trial excluded patients with known bleeding disorders or those already receiving anticoagulation therapy. This pragmatic approach means the results can be immediately applied to routine surgical practice across multiple clinical specialties.
Mechanism and Safety Profile Clarified
Tranexamic acid works by blocking plasmin activation, preventing the breakdown of fibrin clots that naturally form to control bleeding. The drug has been used in trauma medicine since the landmark CRASH-2 trial, but surgical applications remained less well-established until this study.
Concerns about increased thrombotic events proved unfounded in the TRACTION data. The FDA-approved medication showed no significant increase in deep vein thrombosis, pulmonary embolism, or stroke compared to placebo. This safety profile supports broader adoption in surgical protocols where bleeding risk outweighs clotting concerns.
Implementation Challenges and Cost Considerations
Despite tranexamic acid’s low cost and established safety record, uptake in surgical practice has been inconsistent globally. The World Health Organization includes the drug on its Essential Medicines List, but availability varies significantly between high and low-resource settings.
Dr. Katharine Ker, co-investigator from the London School of Hygiene & Tropical Medicine, noted that implementation will require updated surgical guidelines and training programs. The study’s economic analysis suggests that routine use could prevent approximately 100,000 surgical deaths annually worldwide while reducing healthcare costs through shorter hospital stays and fewer transfusions.
Surgical Specialties Poised for Protocol Updates
Cardiac surgery showed the most dramatic benefits in the trial, with tranexamic acid reducing bleeding complications by 35% in this high-risk population. Orthopedic procedures, particularly hip and knee replacements, demonstrated consistent bleeding reduction across age groups and surgical techniques.
General surgery outcomes varied by procedure complexity, but emergency operations showed particularly strong benefits. This finding supports the drug’s potential role in trauma surgery, building on its established use in emergency medicine. Professional societies are now reviewing the data to update their perioperative care guidelines.
Tranexamic acid reduced the risk of major bleeding by 30% with no increase in vascular occlusive events, supporting its routine use in surgery
— TRACTION Collaborative Group, Multiple International Institutions (New England Journal of Medicine, 2024)
What this means
Frequently asked questions
Is tranexamic acid safe for all surgical patients?
The TRACTION trial excluded patients with active bleeding disorders or those on anticoagulation therapy. Your surgical team will assess individual risk factors before administration.
How much does tranexamic acid cost?
As a generic medication, tranexamic acid typically costs less than $10 per dose. The potential savings from reduced transfusions and shorter hospital stays often offset this minimal expense.
When is tranexamic acid given during surgery?
The drug is usually administered intravenously at the start of surgery, with timing optimized based on the specific procedure and patient factors.
The TRACTION trial results are expected to accelerate adoption of tranexamic acid protocols in operating theaters worldwide. With surgical bleeding remaining a leading cause of perioperative mortality, this simple intervention offers immediate potential to improve patient outcomes across diverse healthcare settings. Implementation efforts will focus on training programs and guideline updates to ensure evidence-based practice becomes standard care.
Source: TRACTION for Greater Surgical Use of Tranexamic Acid
🗺️ Find certified Georgian healthcare providers: sheniekimi.ge — Georgia Health Map · 998 clinics · 6,600+ doctors · 2,296 pharmacies
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
